Cost-effectiveness analysis of pemetrexed and gemcitabine treatment for advanced nonsmall cell lung cancer in Turkey

Balçik, Pınar Yalçin; Şahin, Bayram

doi:10.3906/sag-1408-4

Cited by 6 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lung cancer incurs serious economic overburden in diagnosis and treatment according to the increasing number of patients, while 20% of expenditures for all types of cancer treatment are considered to be due to lung cancer [ 43 , 47 ]. The overall cost of cancer care was $124.5 billion in the US in 2010, while costs specific to lung cancer accounted for $12.1 billion [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective

et al. 2021

View full text Add to dashboard Cite

Background This study was designed to estimate economic burden of lung cancer in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice. Methods In this cost of illness study, direct medical cost was calculated based on cost items related to outpatient visits, laboratory and radiological tests, hospitalizations/interventions, drug treatment, adverse events and metastasis. Indirect cost was calculated based on lost productivity due to early retirement, morbidity and premature death resulting from the illness, the value of lost productivity due to time spent by family caregivers and cost of formal caregivers. Results Cost analysis revealed the total per patient annual direct medical cost for small cell lung cancer to be €8772), for non-small-cell lung cancer to be €10,167. Total annual direct medical cost was €497.9 million, total annual indirect medical cost was €1.1 billion and total economic burden of lung cancer was €1.6 billion. Hospitalization/interventions (41%) and indirect costs (68.6%) were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. Conclusions Our findings indicate per patient direct medical costs of small cell lung cancer and non-small-cell lung cancer to be substantial and comparable, indicating the substantial economic burden of lung cancer in terms of both direct and indirect costs. Our findings indicate that hospitalization/interventions cost item and indirect costs were the major cost drivers for total direct costs and the overall economic burden of lung cancer, respectively. Our findings emphasize the potential role of improved cancer prevention and early diagnosis strategies, by enabling cost savings related to drug treatment and metastasis management cost items, in sustainability of cancer treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective

et al. 2021

View full text Add to dashboard Cite

show abstract

“…78 Benzer bir çalışma, akciğer kanserinde kemoterapi ilaçları arasında maliyet açısından seçim yapmayı sağlamak adına Markov bazlı bir model oluşturmuştur. 79 Diyabet için oluşturulan bir modelle sigara ve obezite göz önüne alınarak 2025'e kadar prevalans tahmininde bulunulmuştur. 80 İnme ve kalp hastalıkları için diyet gibi çeşitli önleme politikalarının ne kadar etkili olduğu bir modelle incelenmiştir.…”

Section: Introductionunclassified

Mathematical Models in Healthcare

Yaylalı

2020

Online Türk Sağlık Bilimleri Dergisi

View full text Add to dashboard Cite

Sağlık araştırmalarında matematik modellerin uygulanması yeni olmamakla beraber son yıllarda oldukça yaygınlaşmıştır. Bu artışın nedeni olarak veriyle hesaplama gücündeki artış kadar sağlık maliyetlerinin artması, kaynakların azalması bununla beraber artan yaşam süresi nedeniyle rastlanan kompleks sağlık sorunları da gösterilebilir. Bu çalışma, matematik modellerin sağlık alanındaki uygulamalarını incelemeyi amaçlamakta olup özellikle klinik uygulamaları ve hastalık modellerine önem vermiştir. Bulaşıcı hastalıklar ve kronik hastalıkların modellenmesi bunlara bağlı olarak tedavi ve korunma yöntemlerinin arasından en etkin ve maliyet etkili olanların belirlenmesi önemli bir alandır. Kızamık, grip, kanser ve HIV gibi birçok hastalık ve halk sağlığı sorunu matematik modeller yardımıyla incelenip var olan kaynakların etkin kullanımını sağlayacak karar destek çalışmaları mevcuttur. Bu çalışmada, bu çalışmaların geniş bir özeti kullanılan matematik modelleme yöntemlerinin sınıflandırılmasıyla verilmiştir. Hastalık model yöntemleri olarak Markov modeller, kompartıman modelleri ve ajan temelli benzetim modelleri metot olarak özetlenmiş ve yapılan önemli çalışmalardan bazıları ve Türkiye'de yapılan uygulamalar incelenmiştir.

show abstract

A Systematic Review on Economic Evaluation Studies of Diagnostic and Therapeutic Interventions in the Middle East and North Africa

Nagi

Dewi

Thavorncharoensap

et al. 2021

Appl Health Econ Health Policy

View full text Add to dashboard Cite

Cost-effectiveness analysis of pemetrexed and gemcitabine treatment for advanced nonsmall cell lung cancer in Turkey

Cited by 6 publications

References 8 publications

Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective

Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective

Mathematical Models in Healthcare

A Systematic Review on Economic Evaluation Studies of Diagnostic and Therapeutic Interventions in the Middle East and North Africa

Contact Info

Product

Resources

About